APA (7th ed.) Citation

Garitaonaindía Díaz, Y., Khan, S., Friis, R., Petersen, S., Borch, T., Ruhlmann, C., . . . Ellebaek, E. (2025). 1647P Dabrafenib/trametinib versus encorafenib/binimetinib in BRAF-mutant metastatic melanoma: A real-world propensity score matched survival analysis. Annals of Oncology, 36, S977. https://doi.org/10.1016/j.annonc.2025.08.2275

Chicago Style (17th ed.) Citation

Garitaonaindía Díaz, Y., et al. "1647P Dabrafenib/trametinib Versus Encorafenib/binimetinib in BRAF-mutant Metastatic Melanoma: A Real-world Propensity Score Matched Survival Analysis." Annals of Oncology 36 (2025): S977. https://doi.org/10.1016/j.annonc.2025.08.2275.

MLA (9th ed.) Citation

Garitaonaindía Díaz, Y., et al. "1647P Dabrafenib/trametinib Versus Encorafenib/binimetinib in BRAF-mutant Metastatic Melanoma: A Real-world Propensity Score Matched Survival Analysis." Annals of Oncology, vol. 36, 2025, p. S977, https://doi.org/10.1016/j.annonc.2025.08.2275.